Home

CARB-X, led by Boston University, is accelerating global antibacterial innovation by investing in the development of new antibiotics and other life-saving products to combat the most dangerous drug-resistant bacteria. Our projects represent the world’s largest pre-clinical and early development pipeline of antibiotics and other therapeutics, diagnostics, microbiome and vaccines.

126+

$million

Invested

44

innovative

Projects

7

different

Countries

12

focused on new classes

Pipeline

The Challenge

Accelerate the development of novel antibiotics and other new approaches to address the emergence of drug-resistant superbugs.
Learn More


Spotlight on Science

SciBac is fighting fire with fire by using improved bugs as drugs

Learn More

“Antibiotics transformed modern medicine but overuse and inappropriate use have led to dangerous bacteria developing deadly resistance. Drug discovery must go hand-in-hand with concerted action to ensure antibiotics of last resort are reserved for patients where first-line treatments will not work. And we must ensure these treatments are available in all countries for those who need them.”

— Tim Jinks, Head of Drug Resistant Infections, Wellcome Trust
Watch this video with Tim Jinks on what Wellcome Trust is doing to address the rise of drug-resistant bacteria.

Funders

ASPR
BARDA
WellcomeTrust
NIAID
UK Government

Alliance Partners

Bill and Melinda Gates Foundation

Accelerators and other partners

Events

Events

07.22.19

Boston, MA

Deadline to submit updates to the World Health Organization clinical antibacterial pipeline

07.24.19

Washington, DC

The Role of NIH in Drug Development Innovation and its Impact on Patient Access: A workshop

08.12.19

United Kingdom 

UK Medical Research Council National PhD Training Programme in AMR - Annual Conference

CARB-X News

  • 06.17.2019  |  CARB-X awards Oxford Drug Design funding to develop a new class of antibiotics to treat drug-resistant Gram-negative infections full release

  • 05.14.2019  |  CARB-X funds Debiopharm to develop a new class of antibiotics to treat hospital-acquired pneumonia caused by multidrug-resistant superbug Acinetobacter baumannii full release

  • 04.30.2019  |  CARB-X launches new Funding Rounds to support the development of antibiotics, vaccines, diagnostics and other life-saving products that target drug-resistant bacteria full release

See All News

In The News

  • 07.09.2019  |  We can’t despair about our antibiotic crisis full story

  • 06.29.2019  |  G20 leaders to make united efforts to major economic challenges, including AMR full story

  • 06.19.2019  |  Sustainable Discovery and Development of Antibiotics – Is a Nonprofit Approach the Future? full story

See All News

Sign up for CARB-X news

Get the latest news and announcements from CARB-X.